Oligonucleotide News and Research

RSS

New compound targets APOE gene to reduce Alzheimer's damage in mice

People who carry the APOE4 genetic variant face a substantial risk for developing Alzheimer's disease.

6 Dec 2017

GHIT Fund announces US$16.7 million to support development of new drugs, vaccines and diagnostics

The Global Health Innovative Technology Fund, a unique Japanese public-private partnership formed to battle infectious diseases around the globe, today announced US$16.7 million to support development of new compounds for fighting malaria and tuberculosis, a leishmaniasis vaccine and drug, and a treatment for a long-ignored flesh-eating infection.

31 Oct 2017

Awards for contributions to analytical chemistry and applied spectroscopy announced by Pittcon

The Pittcon Program Committee is pleased to announce this year’s recipients of 13 prestigious awards honoring scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award will be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for laboratory science, which will be held February 26-March 1, Orange County Convention Center, Orlando, Florida.

From Pittcon 10 Oct 2017

Deep Genomics receives $13 million investment to create new class of genetic drugs

Deep Genomics, the AI driven genetic medicine company, received a USD $13 million equity investment led by Khosla Ventures, one of the top venture capital firms. They are accompanied by early stage investment firm True Ventures.

28 Sep 2017

Trial shows safety and tolerability of antisense oligomer for treatment of influenza A

A phase 1 clinical trial published in the British Journal of Clinical Pharmacology found that radavirsen -- an antisense oligomer that inhibits the production of certain influenza proteins -- is safe and well-tolerated in healthy individuals.

20 Sep 2017

Exploration of human genetics reveals new targets to combat heart disease

Again and again, it's the rare among humans that help the rest of us. The exploration of human genetics is revealing new targets to combat heart disease among atypical variants. Mutations in genes that play a role in heart health are the inspiration for a cluster of new heart drugs.

7 Sep 2017

New drug shows promising results for treating spinal muscular atrophy

A drug developed by an Iowa State University biomedical researcher as a potential treatment for spinal muscular atrophy showed promising results in a recently published study.

26 Aug 2017

DNA sensor systems provide highly sensitive monitoring of cancer-related enzyme activity

The development of DNA sensor systems is of great importance for advances in medical science. Now another piece of the puzzle for the development of personalized medicine has been found with the results of a highly sensitive monitoring of cancer-related topoisomerase II enzymes.

24 Aug 2017

New molecular technique can clone thousands of long DNA sequences at the same time

Scientists at Johns Hopkins, Rutgers, the University of Trento in Italy, and Harvard Medical School report they have developed a new molecular technique called LASSO cloning, which can be used to isolate thousands of long DNA sequences at the same time, more than ever before possible.

5 Jul 2017

Targeted treatment slows progression of two degenerative brain diseases in mice

Scientists report a significant step toward combatting two degenerative brain diseases that chip away at an individual's ability to move, and think.

12 Apr 2017

Researchers solve medical mystery through genetics

Researchers have identified the genetic mutation responsible for one patient's serious health problems, finally solving a medical mystery that has endured for over 30 years.

6 Apr 2017

Using Spherical Nucleic Acids to Track and Treat Disease

Spherical nucleic acids are structures that are made by taking a nanoparticle template and using chemistry to arrange short strands of DNA or RNA on the surface of those particles. The spherical core of the nanoparticle creates a spherical arrangement of DNA or RNA, similar to tiny little balls of nucleic acids.

From Pittcon 1 Mar 2017

MIT researchers develop new machine to rapidly produce customized peptides

Manufacturing small proteins known as peptides is usually very time-consuming, which has slowed development of new peptide drugs for diseases such as cancer, diabetes, and bacterial infections.

27 Feb 2017

IDT completes acquisition of GeneWorks' oligo manufacturing business

Integrated DNA Technologies (IDT), through its Singapore subsidiary, today completed the acquisition of the oligonucleotide manufacturing business of GeneWorks Pty Ltd. (GeneWorks) in Australia. This acquisition sees IDT expand its reach in the Asia-Pacific region, following its recent establishment of sales offices in Japan and Korea.

10 Feb 2017

Designer compound may be effective tool for tackling tau-related disorders

In a study of mice and monkeys, National Institutes of Health funded researchers showed that they could prevent and reverse some of the brain injury caused by the toxic form of a protein called tau.

8 Feb 2017

Research unravels molecular mechanisms of antisense oligonucleotides

Stanley T. Crooke, MD, PhD, CEO of Ionis Pharmaceuticals and recipient of the 2016 Lifetime Achievement Award from the Oligonucleotide Therapeutic Society presents a detailed look at the mechanisms that underlie antisense drug activity in the article entitled "Molecular Mechanisms of Antisense Oligonucleotides," published in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

2 Feb 2017

Synthetic molecule appears to reverse Alzheimer's-related neurological damage

Under ordinary circumstances, the protein tau contributes to the normal, healthy functioning of brain neurons. In some people, though, it collects into toxic tangles that damage brain cells.

25 Jan 2017

CSHL researcher-inventor hails FDA approval of new SMA drug

Within a week of Christmas day, a drug called nusinersen will be in the hands of doctors across the nation, who will use it, most urgently, to treat young children with a severe and potentially fatal illness called spinal muscular atrophy (SMA).

26 Dec 2016

Ionis announces FDA approval of first SMA drug in the U.S for pediatric and adult patients

Ionis Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has approved SPINRAZATM (nusinersen) under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.